Comparative effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia.

Abstract:

:Therapy-related changes of the bone marrow fiber content remain a controversial issue in hematopathology. This conflict of opinion firstly depends on difficulties to determine the quantity of fibers exactly (semiquantitative grading, morphometry, reference to cellularity). Secondly, the appropriate selection of patients with specific monotherapies including hydroxyurea (HU) and interferon-alpha (IFN) seems to present some problems. Finally, assessment of myelofibrosis is further biased by the different endpoints of sequential examinations. The latter shortcoming can be improved upon by the calculation of the myelofibrosis progression/regression index which describes the ratio between difference of fiber density and observation time. Using strictly defined therapeutic regimens and intervals between sequential trephine biopsies a stimulating effect of IFN administration on bone marrow fibrosis in Ph1+-chronic myelogenous leukemia (CML) has been found. This result is comparable with the failure of this agent to improve myelofibrosis (and splenomegaly) in a considerable number of patients with allied subtypes of chronic myeloproliferative disorders. This is in contrast to the effect HU exerts which is a more fibrolytic or even stabilizing influence on bone marrow fibrosis. This phenomenon is readily demonstrable by the assessment of dynamic features (myelofibrosis progression index). In addition, patients showing a rapid progression of myelofibrosis during IFN and HU treatment of Ph1+-CML are generally associated with a poor risk outcome and a significant worsening of survival.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Thiele J,Kvasnicka HM

doi

10.3109/10428190109097704

keywords:

subject

Has Abstract

pub_date

2001-09-01 00:00:00

pages

855-62

issue

5

eissn

1042-8194

issn

1029-2403

journal_volume

42

pub_type

杂志文章,评审
  • Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis.

    abstract::To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to chronic lymphocytic leukemia (CLL), we conducted a systematic review and meta-analysis of published case-control studies. We identified 36 studies which reported on polymorphic variation in 19 genes and CLL ri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析,评审

    doi:10.3109/10428194.2013.800197

    authors: Sava GP,Speedy HE,Houlston RS

    更新日期:2014-01-01 00:00:00

  • Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

    abstract::The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians worki...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2015.1131278

    authors: Bruno B,Auner HW,Gahrton G,Garderet L,Festuccia M,Ladetto M,Lemoli RM,Massaia M,Morris C,Palumbo A,Schönland S,Boccadoro M,Kröger N

    更新日期:2016-01-01 00:00:00

  • Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database.

    abstract::B-lineage acute lymphoblastic leukemia (B-ALL) in the elderly population is generally considered to have a poor prognosis. It is unclear whether their survival has improved in the current era. Using the Surveillance, Epidemiology, and End Results database, we selected 717 elderly patients (age≥60) with B-ALL diagnosed...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.991921

    authors: Guru Murthy GS,Venkitachalam R,Mehta P

    更新日期:2015-01-01 00:00:00

  • Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

    abstract::Multiple genes have been identified to cause hereditary predispositions to hematologic malignancies, and characterized by an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and/or aplastic anemia (AA). Referral algorithms for patients who may be at higher risk have been propose...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1630618

    authors: Clifford M,Bannon S,Bednar EM,Czerwinski J,Davis J,Dunnington L,Shahrukh Hashmi S,DiNardo CD

    更新日期:2019-12-01 00:00:00

  • Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction.

    abstract::This study describes our institution's experience using whole brain radiation therapy (WBRT) to treat patients with acute myelogenous leukemia (AML) presenting with hyperleukocytosis. After approval by the institutional review board, we identified patients with AML and hyperleukocytosis using hospital records. The pri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.797088

    authors: Ferro A,Jabbour SK,Taunk NK,Aisner J,Cohler A,Somalya S,Goyal S

    更新日期:2014-01-01 00:00:00

  • Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1).

    abstract::We present a female patient with monoclonal gammopathy of undetermined significance who has remained stable for five years but evolved to overt myeloma in strict temporal relationship with the diagnosis of GH-secreting pituitary macroadenoma. IGF-I serum levels correlated with serum and urine M component. Since the in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000037895

    authors: Tucci A,Bonadonna S,Cattaneo C,Ungari M,Giustina A,Guiseppe R

    更新日期:2003-03-01 00:00:00

  • Angiogenic and lymphangiogenic molecules in hematological malignancies.

    abstract::In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290005964

    authors: Orpana A,Salven P

    更新日期:2002-02-01 00:00:00

  • Acute myelogenous leukemia complicated by acute necrotizing ulcerative gingivitis due to Aspergillus terreus.

    abstract::Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000060573

    authors: Khoury H,Poh CF,Williams M,Lavoie JC,Nevill TJ

    更新日期:2003-04-01 00:00:00

  • Gravin gene expression in acute leukaemias: clinical importance and review of the literature.

    abstract::The aim of this study was to determine the expression of Gravin (a tumor suppressor gene belonging to the A kinase anchoring protein family) in samples of acute leukaemia and to explore its association with the prognosis. The study group consisted of 162 people (137 patients with acute leukaemia and 25 volunteers as c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701377055

    authors: Yildirim M,Paydas S,Tanriverdi K,Seydaoglu G,Disel U,Yavuz S

    更新日期:2007-06-01 00:00:00

  • The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia.

    abstract::The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is active in both normal hematopoiesis and hematological malignancies. Moreover, Janus kinase-2 (JAK2) is the key hematopoietic kinase, and mutations together with single nucleotide polymorphisms (SNPs) of JAK2 have been thoroughly ev...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428191003774960

    authors: Zhong Y,Chen B,Feng J,Cheng L,Li Y,Qian J,Ding J,Gao F,Xia G,Chen N,Lu Z

    更新日期:2010-06-01 00:00:00

  • Fine-Needle Aspiration Cytology and Immunocytochemistry of Abdominal Non-Hodgkin's Lymphomas.

    abstract::The cytomorphology and immunologic characteristics of cells obtained by fine-needle aspiration biopsy of 34 consecutive patients with abdominal lymphomas were analyzed. Nineteen patients had no previous diagnosis, while 15 had previously known or suspected lymphomas. On cytology 21 high-grade and 13 low-intermediate-g...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428198909042461

    authors: Liliemark J,Tani E,Christensson B,Svedmyr E,Skoog L

    更新日期:1989-01-01 00:00:00

  • Facial heliotrope rash as the initial manifestation of acute myelomonocytic leukemia.

    abstract::The association of leukocytoclastic vasculitis or dermatomyositis with malignancies has been reported. We describe a patient who developed a skin rash, histologically compatible with dermatomyositis, which during the course of the disease switched to leukocytoclastic vasculitis, which was accompanied with peripheral b...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709114179

    authors: Tzavara V,Stamoulis K,Aroni KG,Kordossis T,Boki KA

    更新日期:1997-04-01 00:00:00

  • DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

    abstract::This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1397659

    authors: Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

    更新日期:2018-08-01 00:00:00

  • Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?

    abstract::Rituximab is known to affect T cell immune responses. We and others have reported expansions of T large granular lymphocytes (T-LGLs) in lymphoma patients after Rituximab. We report here the immunogenetic profiling of the T cell receptor (TR) gene repertoire in 14 patients who received Rituximab post allo-HCT and expl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1543881

    authors: Papalexandri A,Karypidou M,Stalika E,Kotta K,Touloumenidou T,Zerva P,Paleta A,Mallouri D,Batsis I,Sakellari I,Kotsianidis I,Anagnostopoulos A,Hadzidimitriou A,Margaritis D,Stamatopoulos K

    更新日期:2019-07-01 00:00:00

  • Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.

    abstract::Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patie...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500237450

    authors: Mazzotta S,Gozzetti A,Pirrotta MT,Bocchia M,Sammassimo S,Bucalossi A,Lauria F

    更新日期:2005-12-01 00:00:00

  • Variant and masked translocations in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is characterized by a unique hemorrhagic syndrome, disseminated intravascular coagulation, and the association with the specific (15;17 chi q22-23:q12-21) translocation, which disrupts the retinoic acid receptor alpha (RARA) and the promyelocytic leukemia (PML) genes. The t(15;17) le...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609051752

    authors: Brunel V,Lafage-Pochitaloff M,Alcalay M,Pelicci PG,Birg F

    更新日期:1996-07-01 00:00:00

  • Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature.

    abstract::Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009060321

    authors: Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

    更新日期:2000-06-01 00:00:00

  • Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

    abstract::The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097666

    authors: Montefusco E,Fazi F,Cordone I,Ariola C,Nanni M,Spadea A,Spiriti MA,Fenu S,Mandelli F,Petti MC

    更新日期:2001-02-01 00:00:00

  • Novel therapies for myelofibrosis.

    abstract::Myelofibrosis (MF), including primary, post-essential thrombocythemia and post-polycythemia vera MF, associates with a reduced quality of life and shortened life expectancy. Dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is prominent, even in the absence of the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2015.1037762

    authors: Stein BL,Cervantes F,Giles F,Harrison CN,Verstovsek S

    更新日期:2015-01-01 00:00:00

  • Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

    abstract::A patient with Non-Hodgkin's lymphoma is reported, in which reactivation of the hepatitis B virus was achieved from treatment with rituximab. The patient's HBs antigens were positive on admission, and she tested positive for HBs, HBe, and HBc antibodies, and negative for the HBe antigens. She was treated with a regime...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000151923

    authors: Tsutsumi Y,Kawamura T,Saitoh S,Yamada M,Obara S,Miura T,Kanamori H,Tanaka J,Asaka M,Imamura M,Masauzi N

    更新日期:2004-03-01 00:00:00

  • Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

    abstract::Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1195501

    authors: Harrison CN,Talpaz M,Mead AJ

    更新日期:2016-10-01 00:00:00

  • Thymosin β4 Gene Expression in Leukemic Cells.

    abstract::Thymosin β4 (Tβ4) was originally isolated as a thymic hormone from calf thymosin fraction 5 which exhibited both immune and endocrine functions in vivo and in vitro. Tβ4 is a ubiquitous peptide located in various tissues of mammalian species and other vertebrate classes. Recent studies on the molecular cloning and seq...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109064873

    authors: Kudo J,Shimamura R,Ishibashi H,Niho Y

    更新日期:1991-01-01 00:00:00

  • Rapid Remission Induction and Improved Disease Free Survival in Acute Myeloid Leukaemia Using Daunorubicin, ARA-C, and CCNU.

    abstract::Thirty-four patients with acute myeloblastic leukaemia were treated with DAC, a schedule containing the nitrosourea CCNU (lomustine) 200 mg/m2 given on day one of treatment, together with a standard "3 + 7" remission induction schedule of daunorubicin (DR) and cytosine arabinoside (Ara-C). The results were compared wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050988

    authors: Barrett AJ,Treleaven JG,Samson DM,Evans M,Gaminara E,Foadi M,McCarthy DM

    更新日期:1990-01-01 00:00:00

  • Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.

    abstract::There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000006277

    authors: Lee HK,Wilder RB,Jones D,Ha CS,Pro B,Rodriguez MA,Romaguera JE,Cabanillas F,Rodriguez J,Cox JD

    更新日期:2002-09-01 00:00:00

  • Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease.

    abstract::Although associations between autoimmune disorders (AIs) and the development of myeloid neoplasms have been described, the pathologic features and natural history of these malignancies have not been well characterized. We evaluated whether patients with AIs with acute myeloid leukemia (AML) were similar in nature to p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.736982

    authors: DiNardo CD,Ogdie A,Hexner EO,Frey NV,Loren AW,Luger SM

    更新日期:2013-06-01 00:00:00

  • Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a s

    abstract::The HD-9 trial showed that eight cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine)-escalated led to significant improvements in response rate, progression-free survival and overall survival over COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbaz...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.975804

    authors: Belada D,Štěpánková P,Sýkorová A,Žák P,Smolej L

    更新日期:2015-07-01 00:00:00

  • Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia.

    abstract::Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment respo...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199409049634

    authors:

    更新日期:1994-05-01 00:00:00

  • Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.

    abstract::We present an analysis of 98 consecutive patients with peripheral T-cell lymphoma (PTCL) treated over a 10-year period within Western Australia. The most common frontline therapies were CHO(E)P (47%), HyperCVAD (21%), and reduced intensity therapy or supportive care alone (19%). Median and 4-year overall survival (OS)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1637865

    authors: Kuzich JA,Hutchison AP,Lim KJC,Smallbone P,Denning K,Wright MP,Cull G,Leahy MF,Joske DJL,Radeski D,Purtill D

    更新日期:2019-12-01 00:00:00

  • Fifty years of hairy cell leukemia treatments.

    abstract::Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.565094

    authors: Golomb HM

    更新日期:2011-06-01 00:00:00

  • Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman.

    abstract::Adult T-cell leukemia/lymphoma (ATLL) remains an uncommon disorder outside well-defined risk groups. We describe the case of an Iranian woman, who presented with isolated meningeal relapse of diffuse large-cell lymphoma. The malignant cells coexpressed CD4 and CD8 and HTLV-1 seropositivity was confirmed. Despite combi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409073790

    authors: Seymour JF,Younes A,Cabanillas F

    更新日期:1994-02-01 00:00:00